|
|
| Thomas Lynch Appointed Executive Vice Chairman, and Shane Cooke Appointed Executive Vice President and Chief Financial Officer, Elan Corporation, plc |
DUBLIN, Ireland, July 5 /PRNewswire/ -- Elan Corporation, plc (NYSE: ELN) ("Elan") is pleased to announce the appointment of Thomas G. Lynch to the position of executive vice chairman of Elan and Shane M. Cooke to the position of executive vice president and chief financial officer of Elan. In his new role, Mr. Lynch will work directly with Donal J. Geaney, the chairman and chief executive officer of Elan, on the long-term strategic development of the company. He will be responsible for strategic planning, investor relations, corporate finance, shared services including information technology, human resources and legal services and will remain based in Dublin, Ireland. Mr. Lynch joined Elan as executive vice president and chief financial officer in May 1993 and was appointed to its board of directors in 1998. Mr. Lynch is chairman of Amarin Corporation, plc and a director of Galen Holdings plc, ICON plc and IDA Ireland. Shane M. Cooke joins Elan as executive vice president and chief financial officer and a member of the executive committee of the board of directors. Prior to joining Elan, Mr. Cooke was chief executive of Pembroke Capital Limited, an aviation leasing company, and prior to that held a number of senior positions in finance in the banking and in the aviation industries. Mr. Cooke is a chartered accountant and a graduate of University College Dublin and will be based in Dublin, Ireland. "I am extremely pleased to welcome to Tom and Shane to their new positions," stated Donal J. Geaney. "Tom has played a significant role in the evolution of the strategy which has taken Elan from a small drug delivery company to one of the world's leading biopharmaceutical and drug delivery companies. I am certain that his experience and extensive knowledge of the pharmaceutical industry will continue to be a tremendous benefit to the company as we strive to meet our future objectives." Mr. Geaney continued, "The addition of Shane will add significant strength and experience to our senior management team and I am very pleased he has decided to join the Elan family." Elan is a leading worldwide fully integrated biopharmaceutical and drug delivery company headquartered in Ireland with its principal research, development, manufacturing and marketing facilities located in Ireland, the United States, and Israel. Elan is focused on the discovery, development and marketing of therapeutic products and services in neurology, pain management, oncology, infectious diseases and dermatology and on the development and commercialization of products using its extensive range of proprietary drug delivery technology. Elan's shares trade on the New York, London, and Dublin Stock Exchanges.SOURCE Elan Corporation, plc
back to topRelated links:
Company News On-Call:
CONTACT:
Investors, U.S., Jack Howarth, 212-407-5740,
or 800-252-3526, or Europe, Emer Reynolds, 353-1-709-4000, or
00800-28352600, or Media, Max Gershenoff, 212-407-5740, or
800-252-3526, all of Elan Corporation, plc
NOTE TO EDITORS: Elan Corporation's press releases are available
at no charge through PR Newswire's Company News On-Call fax
service and on the PRN Web site. For a menu of Elan's press
releases, or to retrieve a specific release, call 800-758-5804,
extension 231593, or http://www.prnewswire.com on the Internet.
